Last reviewed · How we verify
Oxycodone Tamper Resistant
At a glance
| Generic name | Oxycodone Tamper Resistant |
|---|---|
| Also known as | Oxycodone Tamper Resistant (OTR) Tablet 10 mg, Oxycodone Tamper Resistant (OTR) Tablet 40 mg, Oxycodone Tamper Resistant (OTR) Tablet |
| Sponsor | Mundipharma (China) Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- OTR Tablet 10 mg Fasted-state Bioequivalence Study (PHASE1)
- OTR Tablet 40 mg Fasted-state Bioequivalence Study (PHASE1)
- OTR Tablet 40 mg Fed-state Bioequivalence Study (PHASE1)
- To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities (PHASE1)
- To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets (PHASE1)
- A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets (PHASE1)
- A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets (PHASE1)
- A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxycodone Tamper Resistant CI brief — competitive landscape report
- Oxycodone Tamper Resistant updates RSS · CI watch RSS
- Mundipharma (China) Pharmaceutical Co. Ltd portfolio CI